Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 14, 2021; 27(6): 487-500
Published online Feb 14, 2021. doi: 10.3748/wjg.v27.i6.487
Published online Feb 14, 2021. doi: 10.3748/wjg.v27.i6.487
Circular RNA circVAPA promotes chemotherapy drug resistance in gastric cancer progression by regulating miR-125b-5p/STAT3 axis
Peng Deng, Bin Hou, Kai Li, Department of Surgical Oncology and General Surgery, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China
Ming Sun, Department of Urology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China
Wen-Yan Zhao, Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China
Tao Zhang, Department of Stem Cells and Regenerative Medicine, China Medical University, Shenyang 110122, Liaoning Province, China
Feng Gu, Department of Ophthalmology, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China
Author contributions: Deng P and Sun M performed the majority of experiments and analyzed the data; Zhao WY performed the molecular investigations; Hou B and Gu F designed and coordinated the research; Li K and Zhang T wrote the paper.
Supported by Natural Science Foundation of Liaoning Province , No. 2019-MS-385 .
Institutional review board statement: This study was reviewed and approved by the First Affiliated Hospital of China Medical University.
Institutional animal care and use committee statement: The animal study was reviewed and approved by the First Affiliated Hospital of China Medical University.
Conflict-of-interest statement: The authors declare no conflict of interest related to this manuscript.
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Feng Gu, PhD, Chief Physician, Department of Ophthalmology, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Heping District, Shenyang 110001, Liaoning Province, China. fenggu78186069@163.com
Received: December 6, 2020
Peer-review started: December 6, 2020
First decision: December 17, 2020
Revised: December 21, 2020
Accepted: January 7, 2021
Article in press: January 7, 2021
Published online: February 14, 2021
Peer-review started: December 6, 2020
First decision: December 17, 2020
Revised: December 21, 2020
Accepted: January 7, 2021
Article in press: January 7, 2021
Published online: February 14, 2021
Core Tip
Core Tip: We concluded that circVAPA contributed to chemotherapy resistance and malignant progression in gastric cancer (GC) by miR-125b-5p/STAT3 signaling. Our findings present novel insights into the mechanism that circVAPA regulates chemotherapy resistance of GC cells. CircVAPA and miR-125b-5p may be considered as potential targets for GC therapy.